With relatively positive news about the orthopedics market from Biomet and Johnson & Johnson (JNJ), investors were primed to hear more of the same from Stryker (SYK).
Unfortunately, Stryker disappointed with numbers that showed real share
loss outside the U.S. and ongoing difficulties in the hospital capital
equipment market. While Stryker remains a quality GARP name to consider
in healthcare, management's credibility is increasingly on the line.
Continue here:
Stryker Looking A Little Stiff And Creaky
No comments:
Post a Comment